Skip to content

Multimodal imaging in evaluating the severity and clinical outcome of COVID-19

The value of multimodal imaging in evaluating the severity and clinical outcome of COVID-19

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059728
Enrollment
Unknown
Registered
2022-05-10
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis, clinical classification and discharge criteria of COVID-19 patients are in line with the Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus (Trial Ninth Edition); 2. Age >= 18 years old; 3. First infection with novel coronavirus.

Exclusion criteria

Exclusion criteria: 1. Have a history of chronic lung diseases or tumors; 2. History of lung surgery or thoracic deformity; 3. The patient did not complete the clinical pulmonary function test 3 months after discharge; 4. The patient did not complete lung multimodal imaging 3 days before and after the clinical pulmonary function test; 5. Quantitative analysis cannot be performed because the image quality is not up to standard (use a list to list the conditions that affect the efficacy or safety evaluation of the study, such as other treatments that are contrary to the inclusion criteria, comorbid diseases, and pregnancy, etc.); 6. Those who use mechanical ventilation during treatment.

Design outcomes

Primary

MeasureTime frame
pulmonary function;Computed Tomograph score;MRI-ventilation;

Countries

China

Contacts

Public Contactzhang guobin

Shanghai Sixth People's Hospital

guobin.zhang@163.com+86 18930177094

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026